Dont believe the hype – we are a long way from an HIV cure

Don't believe the hype – we are a long way from an HIV cure

By Timothy P Lahey, Dartmouth College

HIV has infected over seventy million people but only one of them has been cured: Timothy Ray Brown.

An HIV-positive resident of Berlin, Germany, Brown developed relapsed leukemia in 2006. To treat the leukemia, he underwent special bone marrow transplants that also rendered him genetically resistant to HIV. Brown’s HIV medications were stopped in 2007 and several years later he remains free of HIV.

Brown is historically unique but in recent years scientific journals and the popular press alike have published multiple claims of HIV cures.

In 2012, French scientists announced a “functional cure” of HIV when 14 patients who were treated within months of initial HIV infection remained clinically stable after treatment stopped. Similarly mild cases of HIV disease had been reported even in untreated patients, and unlike Brown the French patients still have detectable HIV in their bodies. Thus the French researchers likened a fairly common piece of good clinical fortune to a historically important cure, and added little more than confusion in the process.

Timothy Ray Brown, the ‘Berlin patient.’
Kevin Lamarque/Reuters

The same year Boston researchers announced that two HIV patients with cancer had undergone standard bone marrow transplants on HIV therapy, and afterward had unusually low levels of HIV in their blood. Preeminent scientists said it was “conceivable and maybe even likely” the Boston patients’ HIV was gone, HIV medications were stopped, the virus rebounded, and several months after it started the Boston celebration came to an end.

In March 2013, doctors announced that an HIV-exposed baby from Mississippi who was treated within hours of exposure was considered cured as once-detectable HIV could no longer be found off of therapy. Scientists speculated HIV never gained a foothold in vulnerable immune cells. In July 2014 it was reported that the Mississippi baby relapsed, most likely because the virus had been lurking all along in those self-same cells.

Echoing the Boston experience, this year two Australian patients were called “HIV-free” and “cleared” of HIV after very low levels of the virus were detected in the blood after stem cell treatments. Both men remain on HIV therapy “as a precaution” so there is no definitive proof of anything more than highly effective therapy and an intense hunger to claim something approximating a cure.

None of these patients, with the exception of Brown, was cured of HIV. Yet in each case a cure has been claimed or the words used to describe the story were so similar to “cure” as to be indistinguishable to the untrained reader.

Why?

Desperation, for starters. HIV has killed over 39 million people so far and every year more than a million more are infected. There is no more urgent public health priority than the discovery of an HIV cure. As a result, when new and exciting HIV findings emerge scientists and journalists can abandon their usual caution and succumb to the temptation to use words like “cure” loosely.

We can’t afford to be complacent about HIV.
Konstantin Grishin/Reuters

Even coolheaded researchers are keenly aware that generating buzz can be the difference between generous funding or the closure of their labs. Salesmanship can devolve into exaggeration as the press conference begins. Journalists and editors, too, are tempted to generate more clicks and sell more papers by freeing the results they report from the scientists’ humdrum caveats.

Desperation and salesmanship aside, even the brightest and most cautious scientists and journalists can get fooled. Many honestly believed, for instance, that the Mississippi baby was free of HIV.

Whatever their motivations, premature intimations of a cure can be dangerous.

The credibility of the HIV research effort is undermined when retractions follow each exciting new announcement of a cure (or whichever phrase like “cleared” is that day’s facsimile). The confusion and skepticism created by repeated retractions can dampen research subjects’ enthusiasm to enroll in studies and even weaken research funding.

The intimations of a cure can also lead to complacency about HIV. Reducing HIV risk behaviors is always challenging, and it is harder when the potency of HIV treatments or the near-availability of an HIV cure make HIV infection seem like, as one newly-diagnosed man told me, “no big deal.” Modern treatments for HIV do keep millions alive for decades and we are closer to a cure than ever before but nonetheless HIV is most definitely a very big deal.

To preserve our scientific credibility, and support our prevention efforts, we should put the word “cure” on a shelf and let it gather a little dust. Someday, when we finally find a cure, a real-life, honest to goodness, checked and double-checked cure, then we can dust off the “C” word and let Timothy Ray Brown know at long last he can have some company in the world’s most elite club.

Until then, we should remember Margaret Heckler. As the Secretary of Health and Human Services, she helped announce Robert Gallo’s discovery of the HIV virus in 1984. Famously she concluded by predicting that we would develop an HIV vaccine within two years. Thirty years later our patients still don’t have an HIV vaccine, or a cure. The next time the lights go up and the microphones click on, let us remember that the way we celebrate progress today cannot forget the unfinished work we take up first thing tomorrow.

The Conversation

This article was originally published on The Conversation.
Read the original article.

What is Psoriasis

Explainer: what is psoriasis?

By Rodney Sinclair, University of Melbourne

Psoriasis is an inflammatory disease of the skin that affects around 2% of the Australian population. That’s enough people to fill the Melbourne Cricket Ground each of the five days of Boxing day test match.

Psoriasis produces angry red scaly plaques on the elbows, knees and elsewhere; severe dandruff on the scalp; nail discoloration and soreness; and inflammatory arthritis of the joints.

The biblical description of “lepra” is now thought to actually be psoriasis rather than leprosy. At that time, affected individuals were stigmatised and cast out from their communities. Some would argue this remains unchanged today as many affected people feel like lepers.

Causes and symptoms

Psoriasis is hereditary; over 30% of affected people can identify a first-degree relative with psoriasis. Research has also identified a number of susceptibility genes, which, when mutated, increase the risk of psoriasis.

Known triggers include certain drugs such as lithium, and antimalarial and antihypertensive medication, but there is no recognised dietary trigger. The mechanism by which these agents trigger psoriasis is not yet understood.

Skin trauma and surgery can cause psoriasis to seed into the wound; when someone with psoriasis has their appendix removed, for instance, and a new patch of psoriasis appears in their appendix scar, this is known as the Koebner phenomenon.

Stress has long been thought to aggravate psoriasis. And itchiness is variable, with some people driven to distraction while others live in harmony with their condition.

Psoriasis causes the skin to renew too rapidly, with insufficient time for the individual cells to fully mature. Normally, it takes six weeks for cells that divide at the base of the epidermis – the uppermost layer of the skin – to differentiate, die, and shed off the skin surface. In psoriasis, this process occurs ten times faster and only takes four to five days.

This rapid cell proliferation causes the skin to thicken. It also requires increased blood flow and nutrients to support this rapid cell proliferation. Increased nutritional requirements stimulate new growth of blood vessels into the skin (angiogenesis), which makes the skin red.

In psoriasis, new cells are stuck together so they appear scaly and flaky.
Maggie Osterberg/Flickr, CC BY-NC-SA

The new cells pushed to the surface are not fully mature and rather than shedding one by one, as mature skin cells do, they are still stuck together, producing skin scaliness and flaking.

Treatment options

Traditional treatments apart from tar and dithranol ointments include steroid creams, calcipitriol cream or ointment (a synthetic derivative of vitamin D), sunlight, artificial ultraviolet B treatment, and tablets such as acitretin (an oral retinoid), cyclosporine (a drug to prevent organ transplant rejection), and methotrexate (a chemotherapy agent).

Each of these treatments work well for some people but not all. And cumulative side effects often limit their continued use even among responders.

Recent years have seen a quiet revolution in the treatment of psoriasis. Gone are the messy and smelly tar and dithranol ointments. Molecular biology research has delivered a host of new therapies called biologics.

Biologics are a class of treatments where monoclonal antibodies are manufactured synthetically to target a specific molecule in the chain reaction that produces the skin inflammation seen in psoriasis.

Depending on the biologic agent used, a single injection into the skin repeated either fortnightly, monthly or quarterly can produce complete clearance of even the worst psoriasis within weeks. It can also keep the skin disease at bay.

The first biologic therapies for psoriasis targeted the tumour necrosis factor alpha molecule, a master cytokine. Cytokines are cell signalling molecules involved in the regulation of inflammation. These biologics are also used to treat rheumatoid arthritis, Crohn’s gastrointestinal disease, and other inflammatory diseases of the body.

The next generation of agents targeted interlukin 12 and 23. Interlukins are a class of cytokines initially found in white blood cells, but now known to be produced by and act on a broad range of cells in the body. Newer agents are directed at the interleukin 17 molecule.

The cost of these agents is in the range of A$5,000 to A$30,000 per year. The government subsidises the cost of these medications through the Pharmaceutical Benefits Scheme for only the most severely affected. This creates a unusual paradox for dermatologists: treating mild disease is now more complex than treating severe disease.

The Conversation

This article was originally published on The Conversation.
Read the original article.

Working out PTSD- exercise is a vital part of treatment

‘Working out’ PTSD – exercise is a vital part of treatment

By Simon Rosenbaum, George Institute for Global Health

In 1954, the first director-general of the World Health Organisation, Dr Brock Chisholm, famously stated: “Without mental health there can be no true physical health.”

More than half a century later, we have large numbers of studies backing up his belief. Surprisingly, given the known effectiveness of exercise as an additional part of treatment for depression, there have been few studies investigating the use of exercise in the treatment of people with severe PTSD.

Post-traumatic stress disorder often occurs after potentially life-threatening events. PTSD is common in certain occupations, the armed forces and police officers. The US Department of Veterans Affairs estimates that 10% of women and 4% of men are affected in the general population, with rates as high as 31% among combat veterans. In Australia, it is estimated up to 5% of people will experience PTSD, with a four-fold increase in PTSD cases since Australian troops first went to war in Afghanistan in 2001.

PTSD affects more than just mental health. It is linked with a greater risk of chronic conditions such as diabetes, obesity, alcohol abuse and cardiovascular disease. Gaining weight and losing fitness are also unlikely to help aid recovery from such a debilitating and all-encompassing illness, and can often make symptoms worse.

Exercise as treatment

Because exercise can have a positive effect on depression, we suspected that exercise would have a similar effect on PTSD. So we conducted a clinical trial with 81 people, mostly former soldiers and police officers, in residential treatment at St John of God Hospital in Richmond, Australia.

In our study, we randomly assigned patients to two types of treatment. Half received usual care, a combination of group therapy, medication and psychotherapy. The other half received a structured, individualized exercise program combining walking and strength-based exercises in addition to usual care, for a period of 12-weeks.

The exercise program was low-cost and used elastic exercise bands to replicate traditional gym exercises such as bench press and squats. The exercises were tailored to each individual in order to maximize motivation and continue to take part.

Since poor motivation is a key symptom of severe depression, asking people who are experiencing severe mental distress to exercise can be difficult. For many of the participants in our study, their early exercise program simply involved getting up out of bed, walking to the nurses’ station twice and repeating.

In the following session, this could increase by adding an extra lap to the nurses’ station, in addition to various resitance-based exercises.

Program details were recorded in the participant’s exercise diary. Exercise goals were established and reviewed together with the exercise physiologist. We supplied pedometers (step-counters) allowing patients to keep track of their overall daily step count and set specific goals.

More exercise, better health

Patients who received the exercise program in addition to usual care showed greater improvements in symptoms of PTSD, depression, anxiety and stress compared to those who received usual care alone. And the benefits of the exercise program extended well beyond improved mental health.

Patients who only received usual care gained weight, walked less and sat more over the 12-week period. Patients who completed the exercise intervention in addition to usual care, however, lost weight and reported significantly more time walking and less time sitting. Ultimately this reduced their overall risk of developing heart disease.

Similar results were found demonstrating a positive effect of the exercise program on sleep quality, known to be poor amongst people experiencing PTSD.

Exercise as treatment

Importantly, as a result of this research St John of God hospital has now included exercise as a key part of its PTSD treatment program. Promising research from the UK has shown a positive effect of surfing on improving the well-being of combat veterans. Importantly, charities such as Soldier On in Australia, Help For Heroes and Surf Action in the UK are helping to promote physical activity and facilitate engagement among contemporary veterans.

Our findings are in line with previous research in the US demonstrating a positive effect of yoga for PTSD, and provides support for the inclusion of structured, individualized exercise as a part of PTSD treatment.

For the first time, this research shows that individualized and targeted exercise programs can improve the physical and mental health of PTSD patients. Further research is currently underway at the University of California, San Francisco.

While it is true that without mental health there can be no true physical health, exercise appears to be vital for both.

The Conversation

This article was originally published on The Conversation.
Read the original article.

Risk and respect- what to know about disclosing mental illness at work

Risk and respect – what to know about disclosing mental illness at work

By Sarah von Schrader, Cornell University

Deciding to disclose information about a non-obvious disability at work is complicated and potentially risky, no matter what you do for a living. For people with a mental health issue, like bipolar disorder or PTSD where stereotypes and bias are prevalent, the risk can be even greater.

This has become an important topic as employers try to reach voluntary affirmative action goals around disability employment. Federal contractors are required to try to achieve a workforce that is about 7% people with disabilities (these include conditions like major depression and bipolar disorder). As a result, employers are considering how to handle disability disclosure like never before.

Affirmative action goals aside, there is a business case to made for disclosure. Workers with depression, for example, cost employers an estimated US$44 billion per year due to absence and reduced on-the job-productivity. Letting employees come forward about their condition to find better work arrangements and support makes financial sense.

Disclosure and risk

Along with other researchers, I examined disclosure in a study of 600 people with disabilities, half of whom had mental or emotional health conditions. We learned about the perceived risks and actual consequences of disclosure as well as about what may facilitate the decision to disclose and the role employers play.

We found that the concerns of those with mental health issues were not so different from those with other disabilities. People with all types of disabilities feared being fired, of losing out on future opportunities, and of possible ridicule or harassment by coworkers or managers. One respondent said, “I do not want to be viewed as a disabled person and then as an employee … I want to ensure that I am viewed as a valued employee who happens to have a disability.”

Why disclose?

Under the Americans with Disabilities Act (ADA) a person must disclose their disability in order to get support or what’s formally known as an accommodation. For an individual with mental illness, this could be time, place or schedule flexibility, a service animal or another easy-to-implement, low-cost or free accommodation. They can help an employee to be more productive and engaged at work and are the biggest reasons people decide to disclose a non-visible disability in the workplace.

The dialogue between employees and their employers about accommodation should be ongoing because what works best may change over time. A flexible, creative and interactive dialogue during the accommodation process can make it more successful.

In fact, respondents rated having a supportive relationship with their supervisor as the second most important factor in deciding to disclose a mental illness. From other research, we know that individuals are much more likely to disclose a disability to a supervisor than to someone from human resources or on equal employment opportunity survey.

But supervisors need support and education to confront biases. Training on disability awareness, the ADA, and accommodation can help prepare supervisors for the disclosure conversation. Knowledge of disability-related resources both within the organization and in the community can build supervisor confidence.

A little flexibility can go a long way.
Image of woman at desk via Ammentorp Photography/Shutterstock

Respect and trust

Despite fears of limited opportunities or harassment, the vast majority people in our survey had neutral or even positive experiences with their disclosure. We found that those who reported positive disclosure experiences often said things like: “My boss respected me and understood the difficulties I have” and that “[disclosure] depends on the responsiveness of co-workers, supervisors, and general work environment.”

Respondents indicated that visible employer commitment to disability was important in their decision to disclose. Seeing other employees with disabilities succeed, seeing their employer actively recruit people with disabilities, or seeing disability included in a company diversity statement made the decision to disclose easier. However, company policies are not enough.

As one person said, “I would be wary of disclosing until I saw how the employer actually treated employees with mental health issues, not just their stated policy. There would have to be trust in my supervisors and colleagues.”

What and when to disclose

A colleague compared disability disclosure to peeling an onion: there may be lots of layers to disclosure. What is shared with a coworker may be different from what is shared with human resources. Someone may choose to disclose only one of multiple disabilities to an employer – perhaps only the disability where a workplace accommodation would help. There is also the decision of when to disclose.

In our survey, people said they felt disclosure could be safer later in the employment process. This might mean waiting until after they are hired or have had a chance to prove their value. But it can be stressful to put off this conversation, as one respondents said “it is certainly less stressful to have it out in the open than to be concerned about having to hide it and not wanting anyone to find out”.

Disclosure can also have a positive impact for others with similar disabilities. One person said, “I am not ashamed of my disability, and I would hope that my disclosure would help someone else with a disability in seeking employment.”

The Conversation

This article was originally published on The Conversation.
Read the original article.

First Lady calls for innovation in AIDS fight

By EDWIN MUSONI ( Photo: The New Times: First Lady Jeannette Kagame (C) together with other delegates at the closure of the International HIV Reasearch Conference in Kigali.)

The First Lady, Jeannette Kagame, has called for innovation in the fight against HIV/Aids as an additional mechanism in the prevention and treatment of the virus.

Mrs Kagame was yesterday speaking at the closure of the seventh edition of the International HIV Research Conference.

The three-day conference held under the theme: ‘Using evidence to save lives’ drew 400 global experts and researchers on HIV/Aids from 10 countries.

Mrs Kagame told participants that “by exchanging evidences and experiences, we are better able to continue the collective struggle against HIV/Aids.”

She commended the researchers for working hard to mitigate the impact of HIV/Aids on the world population.

“Even though we have not mastered the virus and its mutations, we have indeed made significant progress in treating it and preventing its transmission,” she said.

Mrs Kagame outlined measures Rwanda has put in place to combat HIV/Aids, pointing out that Africa is the most affected continent representing 90 per cent of the global HIV burden.

“HIV/Aids rates are aggravated by conflicts, socio-economic inequality, gender based sexual violence and forced migration,” Mrs Kagame said.

“We need more innovative ways to sustain the gains made. It is good we have learnt valuable lessons about the nature of HIV infections,” she added.

She said the challenge of HIV forces ‘us to stretch our abilities beyond what we have thought possible.’

During the conference on Wednesday, delegates launched a campaign to engage the media in awareness and early treatment campaign to reduce mortality and mobility.

The one-year campaign will run throughout 2015.

Latest statistics indicate that the prevalence rate in the country stands at 3 per cent.

Dr Sabin Nsanzimana, the head of HIV/Aids unit at Rwanda Biomedical Centre, said the low prevalence rate since 2010 is an indication that HIV/Aids spread is under control.

“A study conducted through collaborative efforts of local and international researchers gives us hope about life expectancy for people who are on ARVs in Rwanda. Data indicates that a 15-year-old HIV positive person taking ARVs can live for 35 more years while a 40-year-old of similar status and taking ARVs can live for more 30 years meaning that this person can live up to the age of 70,” Nsanzimana said.

He added that another study presented at the conference proved that ARVs, do not only help those living with HIV/Aids but also the general public.

“Increase of antiretroviral treatment by 10 per cent is going to reduce HIV transmission by six per cent. Also transmission of the virus from mother to child has reduced by 1.8 per cent in the recent past.”

Although the government has increased its financial allocations to HIV prevention and treatments, Nzanzimana observed that there has been a sharp decline in external funding to HIV which calls for more investment in innovation to counter the challenge.

The international conference was also attended by children from all the 30 districts of the country who presented their views to delegates in regards to HIV prevention and treatment for children.

“Parents should openly discuss issues related to HIV prevention with their children while government should provide support for children infected and affected by HIV,” said Aline Irasoneye, who spoke on behalf of the children participants.

In detailing support to children infected with HIV, Irasoneye proposed a special school feeding programme to ensure that infected children get a nutritious meal and the use of peer educators within villages to help infected children take their ARVs.

This article was originally published on the New Times Rwanda

Read the original article

 

New 15 minute saliva test for Ebola may be big boost in the fight against outbreak

New 15-minute saliva test for Ebola may be big boost in the fight against outbreak

By Peter Barlow, Edinburgh Napier University

A new diagnostic test for Ebola that can measure viral proteins in the blood or saliva and give results within 15 minutes is going to be tested in Guinea. The British-led project will determine the effectiveness of the test in samples isolated from patients suspected of having Ebola; the results will be validated against routinely used methods for establishing if there is an Ebola infection.

A 15-minute test for Ebola would be an enormous leap forward for clinicians and public health workers who are still fighting a daily battle to contain the virus – and could prevent it from spreading to other countries.

This encouraging news comes as a new warning was issued by Tony Banbury, the head of the United Nations Mission for Emergency Ebola Response, who said there was still a “huge risk” that Ebola could move to other countries across the globe. As the death toll from the deadly virus approaches almost 7,000 victims, with more than 16,000 current infections, the challenge to contain the virus is still at the forefront of the minds of public health officials in West Africa and across the world.

Current screening methods

Many countries including the US and Canada, the UK, France and Belgium have begun screening passengers who arrive on flights from the West African countries most severely affected with the Ebola virus.

This screening includes a questionnaire, which attempts to identify if contact with an Ebola patient could have occurred – but there are issues with this if someone isn’t truthful or is unaware of contact. Testing for elevated body temperatures in travellers was also used to try and determine which individuals should be forwarded for further diagnostic assessment.

But these screening procedures lack specificity for the Ebola virus and are certainly not 100% effective – someone could be carrying the Ebola virus, for example, without yet showing symptoms.

The new 15-minute test can recognise components of the virus in blood or saliva samples – the viral proteins – from suspected Ebola patients. Other tests tend to require extensive and time-consuming amplification of the viral genome, measuring the growth of the virus in cell cultures, or even quantifying the concentration of antibodies against the virus in a patient’s blood. These methods can take anything from several hours to several days depending on virus and technique.

Notably, the reagents – the substances used in chemical analysis – that are needed to perform the 15-minute test are also stable at room temperature and can be contained in a mobile suitcase laboratory. This means test materials can be transported to remote environments without requiring cold storage, unlike laboratory-based diagnostics which may require constant storage in a fridge.

The research, which is still in pilot stage, is funded by the Wellcome Trust and the Department for International Development, who have also been fast-tracking funding for an Ebola vaccine. It is likely that if it is found to be a robust method of screening for Ebola virus, it could rapidly be rolled out to help with the containment of the current outbreak and allow immediate diagnosis of Ebola patients in remote locations. It could also have significant and fundamental implications for air travellers.

Another test called EbolaCheck is also in development, which would give an indicator of the presence of Ebola in body fluids within 40 minutes.

Outbreaks and airports

It is important to fully consider how else a 15-minute test could be used if the initial trial is validated and shown to be successful. In addition to being used in a remote area involved in an Ebola outbreak, it could also likely have significant implications for how airline passengers are screened across the world. Saliva tests for Ebola could become standard practice at airports with flights arriving from the countries most affected by the virus.

In the event of additional outbreaks, the test could be rapidly deployed at security screening and border-control stations. It is also possible to envisage the test becoming mandatory, but – despite the peace of mind for some – being forced to take a saliva test and wait for 15 minutes while going through security could well be considered highly invasive by many people.

Airport screening aside, there is no doubt that the development of rapid diagnostic tests for any highly pathogenic virus, including Ebola, is key in the fight against deadly emerging infections. Increased speed in diagnosing an infection translates to quicker treatments for those people with the virus and increased safety for those who do not.

The Conversation

This article was originally published on The Conversation.
Read the original article.

What you need to know about mucus and phlegm

Health Check: what you need to know about mucus and phlegm

By David King, The University of Queensland

We tend to notice mucus only when it’s abnormal and the sticky fluid is expelled from orifices. But actually it’s pretty amazing stuff. Every moment of our lives mucus is protecting our internal organs, including the sexual organs and bowels. Here, though, we’ll focus on the airways.

What is mucus?

Mucus is 95% water, 3% proteins (including mucin and antibodies), 1% salt and other substances. Mucin droplets absorb water and swell several hundred times in volume within three seconds of release from mucus glands. Mucus strands form cross links, producing a sticky, elastic gel.

The solid gel layer acts as a physical barrier to most pathogens and the constant flushing movement prevents the establishment of bacterial biofilms. However, the pore size of the gel mesh means small viruses can easily penetrate it.

Anatomy of the airways

Both nasal cavities combined have a surface area of 150 square centimetres, aided by bony folds on their side walls. The turbulent airstream means 80% of particles are filtered here, so the adhesive properties of mucus are vital.

The blood flow to the nose varies with changing outside temperature, acting like a reverse-cycle air conditioner for the lungs.

Mucus is constantly produced (although in lesser quantities during sleep) and moved along. The mucus carries with it dead cells and other dust and debris, ending up in the stomach for recycling.

Many cells lining the airways have a long, tail-like hair, called cilia. Cilia beat at ten to 12 times per second, propelling mucus at one millimetre per minute.

Lung airways also have cilia, working hard to move mucus uphill against gravity. Mucus from the lungs is sometimes termed “phlegm”, and then “sputum” once it has been spat out.

The nose produces over 100 millilitres of mucus a day and the lungs produce approximately 50 millilitres daily.

Mucus and airways disease

Mucus assists in fighting infection when white blood cells and antibodies are excreted into the mucus film. The amount of mucus and watery liquid is increased to flush away infection, irritants or allergens.

Viruses that damage respiratory lining cells also damage cilia, so a runnier mucus layer is more easily propelled. When the cilia just can’t keep up, the body deploys other strategies such as coughing, blowing the nose, sneezing and every parent’s favourite, the snotty nose.

Chronic lung disease such as chronic bronchitis and cystic fibrosis cause mucus glands to multiply three to four times above normal levels, resulting in more viscous mucus that the cilia can’t easily clear.

Your airways use mucus to catch particles and cellular debris and move it uphill for excretion.
Hey Paul Studios/Flickr, CC BY

Dehydration and some medications such as nasal decongestants reduce the effectiveness of cilia by lowering the ciliary beat frequency.

Even a frequent and repetitive cough can fatigue the cilia, leading to slower transit and increased stickiness of the mucus. That’s why many people have a prolonged “post-nasal drip” cough after colds and hay fever, as the mucus that has dripped down from the back of the nasal cavity isn’t cleared.

Saline (salt solutions) increase ciliary beat frequency and have demonstrated benefit in respiratory disease, from sinusitis to cystic fibrosis.

A ‘chesty cough’?

There is a common belief that a moist (chesty) cough indicates a chest infection. But in young, healthy people, post-nasal drip of mucus is more common than bronchitis or a chest infection.

It is extremely difficult to judge whether the sputum in the throat arose in the lungs or dripped down from the back of the nasal cavity. And mucus vibrating near the vocal cords sounds chesty no matter where it came from.

But the timing of cough may be helpful for diagnosis: a post-nasal drip cough is worse when lying down and for a while after rising from bed in the morning.

Green phlegm

Another misconception is that green mucus indicates bacterial infection and thus requires antibiotic treatment.

A number of research studies have shown poor correlation between mucus colour and significant infection. The yellow and green colours actually come from white blood cells (leucocytes) that fight infection, but are also more prominent the longer the mucus has “stuck around for”. So morning sputum may be more coloured than later in the day.

The diagnosis of a bacterial infection is made when a combination of symptoms and findings exists, with mucus colour not being the most important of these.

Unfortunately this misconception extends to some GPs. Patients with green sputum are prescribed antibiotics three times more often than patients coughing clear sputum. However, for patients with a bad cough, this prescription did not improve their recovery.

Snotty noses are a flood of mucus to wash away the viral ‘cold’. But it’s no excuse not to use a tissue.
Joshua Wachs/Flickr, CC BY-NC-ND

Mucus can be colourful stuff, extending from clear to yellowy-green, but also orange, brown and grey.

Orange and brown comes from the presence of blood in mucus, of variable concentrations and ages. This blood commonly comes from the nose, due to inflammation, infection or side effects of nasal medication, without an obvious nose bleed.

Blood-stained sputum from the lungs may indicate a more serious illness.

Milk and mucus

Many people believe milk and dairy products stimulate the production of extra mucus, so should be avoided in those with hay fever and asthma. This perception arises from the short-term change in consistency of mucus and saliva in the mouth and throat.

But research evidence shows no difference in measured mucus output. Another “blinded” study compared identical-looking dairy and soy products and found no difference in amount or perception of mucus.

To spit or swallow?

I’m occasionally asked whether swallowing mucus produced with a respiratory infection is harmful. It’s not; luckily the stomach works to neutralise bacteria and recycle the other cellular debris.

Some people do report a queasy feeling in the stomach during such infections. This is more likely due to air swallowed from repeated throat clearing and the infection itself, rather than increased mucus getting to the stomach.

Freelance journalist and translator Claire Dupré assisted with the drafting of this article.

The Conversation

This article was originally published on The Conversation.
Read the original article.

2014 International HIV Research Conference

2014 International HIV Research Conference

Where: Serena Hotel, Kigali- Rwanda

When: 3rd to 5th December 2014.

Theme of the conference : “Using evidence to save lives”.

These are useful links and documents:

2014 International HIV Research Conference ( Official Web Pages)

Registration

call_for_abstracts__final (1)

Conference_agenda-_Day1

Conference_agenda-_Day2

Conference_agenda-_Day3

 

KigaliHe.com

 

why do I sweat so much and how can I stop it?

Explainer: why do I sweat so much and how can I stop it?

By Rodney Sinclair, University of Melbourne

Everybody sweats, some more than others. It’s a physiological reaction to heat and the body’s mechanism to regulate core temperate.

Individual sweat rates vary and are influenced by factors such as ambient temperature, humidity, air movement, exercise intensity, clothing and body size. Daily fluid loss from sweat may be as little as 100ml per day for a sedentary person in a cool climate or as much as nine litres per day for elite athletes training in hot and humid climates.

The body has two main types of sweat glands. Eccrine glands are found all over the body. These are supplied by sympathetic nerves and activated in response to heat and stress. Apocrine glands are found mainly in the armpits and groin and contribute to body odour rather than moisture.

Body odour is produced when bacteria break down the protein secreted in apocrine sweat. High salt levels in the eccrine gland sweat inhibit bacterial growth, making eccrine sweat odourless.

The human stress response, also known as the fight-or-flight response, involves secretion of adrenaline by the adrenal gland. The adrenaline released travels in the circulation to the skin and activates eccrine sweating. Many people are familiar with the sensation of sweaty palms at moments of stress or anxiety.

Deodorants

Roll-on and spray antiperspirants are sufficient for all but the most severe sweaters. The main ingredients, aluminium chloride and aluminium chlorohydrate, have stood the test of time as a safe and effective way to control underarm perspiration.

Ban Roll-on Deodorant magazine advertisement from 1957.
Classic Film/Flickr, CC BY-NC

Antiperspirants can be used anywhere on the body. The aluminium reacts with the electrolytes in the sweat to form a gel plug that blocks the sweat duct. This blockage feeds back to the sweat gland and inhibits sweat secretion.

The first commercial deodorant, Mum, was developed and patented by a US inventor in 1888.

Bristol Myers bought the company in 1932 and in the late 1940s developed a roll-on applicator based on the newly invented ball-point pen. In 1952, the company began marketing the product under the name Ban Roll-On in the United States. It is still sold under the name Mum in the United Kingdom and Australia.

Long-acting high-intensity preparations containing aluminium chloride hexahydrate have become increasingly available in recent years and many heavy sweaters can gain control with these agents. Some products are sold in pharmacies over the counter, without the need for a prescription.

Hyperhidrosis

Approximately 3% of the population suffer from some form of excessive sweating, called hyperhidrosis. About half of those affected have axillary (or underarm) hyperhidrosis.

If over-the-counter products don’t give you relief, it might be time to visit a specialist. In the assessment, the dermatologist will take a history to establish the nature and severity of the sweating and the impact it is having on your life.

The specialist will examine the skin for irritation or a rash. They will also take blood tests to exclude conditions such as thyroid disease and diabetes, which can sometimes cause excessive sweating. Some antidepressants can also make sweating worse.

Thyroid disease, diabetes and some antidepressants can cause excessive sweating.
Asim Bharwani/Flickr, CC BY-NC-ND

If you have hyperhidrosis, or excessive eccrine sweating, the dermatologists may prescribe tablets to reduce the nerve activation of sweat glands. Or they may recommend iontophoresis treatment, which uses water and a mild electrical current to deal with sweaty palms and soles.

Another option is to use Botox to paralyse the eccrine glands and stop the sweating dead. Botox is listed on the Medicare Benefits Schedule for underarm sweating in those who have tried everything else without success.

Botox is injected into the skin of the armpit superficially. While the injections are moderately uncomfortable, no local anaesthesia is required. The armpits will then remain completely dry for somewhere between six and nine months.

Botox can also be used for sweating elsewhere on the body, but without the Medicare rebate. The cost can be close to A$1,000, depending on the size of the area to be treated and the amount of Botox required.

Hyperhidrosis was traditionally treated with sympathectomy surgery, which involves cutting the nerves that trigger sweating, but this is becoming a thing of the past. While some people get good results, compensatory hyperhidrosis can cause breakout sweating in previously unaffected areas of the body. Some people also find the effects wear off over five to ten years.

Fortunately, compensatory hyperhidrosis is rare after Botox. In fact, there are few complications.

If you are concerned about excessive sweating, consult your GP, who can refer you to a specialist if required.

The Conversation

Rodney Sinclair does not work for, consult to, own shares in or receive funding from any company or organisation that would benefit from this article, and has no relevant affiliations.

This article was originally published on The Conversation.
Read the original article.

18th RMA ANNUAL SCIENTIFIC CONFERENCE

The Rwanda Medical Association is organising the 18th annual scientific conference which is scheduled to take place on 06th and 07th February 2015, at Sports view Hotel, Kigali. The conference is open to medical doctors and other health professionals. The theme of the 2014 conference aims at raising awareness among doctors of the nutritional challenges met in Africa in general and Rwanda in particular .

Here below are the call for abstacts and the Agenda.

Call for Abstracts RMA Scientific Conference Dec 2014 (1)

Agenda Scientific Conference 12_13 Dec 2014

 

Kigalihe.com